Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex
- PMID: 21175212
- PMCID: PMC3071873
- DOI: 10.1021/jm101359c
Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex
Abstract
The binding of zonisamide to purified, recombinant monoamine oxidases (MAOs) has been investigated. It is a competitive inhibitor of human MAO B (K(i) = 3.1 ± 0.3 μM), of rat MAO B (K(i) = 2.9 ± 0.5 μM), and of zebrafish MAO (K(i) = 30.8 ± 5.3 μM). No inhibition is observed with purified human or rat MAO A. The 1.8 Å structure of the MAO B complex demonstrates that it binds within the substrate cavity.
Figures




Similar articles
-
Leflunomide, a Reversible Monoamine Oxidase Inhibitor.Cent Nerv Syst Agents Med Chem. 2016;16(2):112-9. doi: 10.2174/1871524915666150824154329. Cent Nerv Syst Agents Med Chem. 2016. PMID: 26299850
-
Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives.Bioorg Med Chem Lett. 2015 Mar 15;25(6):1206-11. doi: 10.1016/j.bmcl.2015.01.061. Epub 2015 Feb 4. Bioorg Med Chem Lett. 2015. PMID: 25701250
-
Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B.Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12684-9. doi: 10.1073/pnas.0505975102. Epub 2005 Aug 29. Proc Natl Acad Sci U S A. 2005. PMID: 16129825 Free PMC article.
-
Inhibitor design for monoamine oxidases.Curr Pharm Des. 2013;19(14):2529-39. doi: 10.2174/1381612811319140004. Curr Pharm Des. 2013. PMID: 23116392 Review.
-
[Computer modelling of monoaminoxidases].Biomed Khim. 2015 Mar-Apr;61(2):265-71. doi: 10.18097/PBMC20156102265. Biomed Khim. 2015. PMID: 25978392 Review. Russian.
Cited by
-
Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies.Molecules. 2021 Apr 22;26(9):2430. doi: 10.3390/molecules26092430. Molecules. 2021. PMID: 33921982 Free PMC article.
-
Design, synthesis and evaluation of 1-(1,5-bis(4-substituted phenyl)-2-methyl-1H-pyrrol-3-yl)-N-methylmethanamines as SERT inhibitors with potential antidepressant action.RSC Med Chem. 2022 Oct 29;14(2):393-402. doi: 10.1039/d2md00243d. eCollection 2023 Feb 22. RSC Med Chem. 2022. PMID: 36846366 Free PMC article.
-
Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease.Parkinsons Dis. 2018 Dec 18;2018:8626783. doi: 10.1155/2018/8626783. eCollection 2018. Parkinsons Dis. 2018. PMID: 30662707 Free PMC article.
-
Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.Front Neurosci. 2016 Nov 10;10:492. doi: 10.3389/fnins.2016.00492. eCollection 2016. Front Neurosci. 2016. PMID: 27891070 Free PMC article. Review.
-
Computational Drug Target Screening through Protein Interaction Profiles.Sci Rep. 2016 Nov 15;6:36969. doi: 10.1038/srep36969. Sci Rep. 2016. PMID: 27845365 Free PMC article.
References
-
- Uno H, Kuokawa M, Masuda Y, Nishimara H. Studies on 3- substituted 1,2-benzisoxazole derivatives, 6. Synthesis of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J. Med. Chem. 1979;22:180–183. - PubMed
-
- Murata M. Novel Therapeutic Effects of the Anti-convulsant, Zonisamide, on Parkinson's Disease. Curr. Pharm. Des. 2004;10:687–693. - PubMed
-
- Yang LPH, Perry CM. Zonisamide in Parkinson's Disease. CNS Drugs. 2009;23:703–711. - PubMed
-
- Okada M, Kaneko S, Hirano T, Mizuno K, Kondo , Otani K, Fukushima Y. Effects of Zonisamide on Dopamminergic System. Epilepsy Res. 1995;22:193–205. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Chemical Information